Indian Institute of Technology Delhi and Agilent to set up incubator site for bioanalytical science

Public research, development and manufacturing company, Agilent Technologies (CA, USA) has announced the signing of a memorandum of understanding with the Indian Institute of Technology Delhi (IIT Delhi, India). The memorandum confirms that Agilent is contributing funds to support an incubator site for bioanalytical science based at IIT Delhi.

Bioanalytical science research at IIT Delhi examines and reports on the quality of biotherapeutic products for the Indian market. The funding is intended to facilitate researchers at the institute establish global best practices for characterizing biopharmaceuticals.

The funds contributed by Agilent come as a result of Agilent’s corporate social responsibility initiative, which aims to enhance the quality and safety of biotherapeutics by training bioanalytical science researchers on protein characterization.

The funding will be under the IIT Delhi’s Department of Biotechnology Center of Excellence for Biopharmaceutical technology and will help incubated bioanalytical science startups to perform protein analysis. Results from such analysis could provide critical information to policy makers to allow the right decisions to be made on biotherapeutic products in India.

Bharat Bhardwaj, Country General Manager (Agilent India), commented: “We are excited to embark on this initiative with IIT Delhi, an institute with the country’s brightest minds engaged in research and technology. Agilent’s relationship with IIT Delhi goes back decades. The new memorandum of understanding that we have signed will further strengthen our relationship and will enhance the ability to do cutting-edge research, which can be used to improve the quality of life for the community at large, through the application of new innovations.”

“We are happy to be associated with Agilent,” added Anurag Rathore, Coordinator of the Center of Excellence for Biopharmaceutical Technology (IIT Delhi). “Agilent’s broad range of technologies will further boost our efforts at the Centre of Excellence for Biopharmaceutical Technology. This mutually constructive and productive partnership will hopefully lead to promising results for the entire biotherapeutics ecosystem.”

Source: www.agilent.com/about/newsroom/presrel/2020/29jan-ca20005.html